Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by princeofcuton May 14, 2015 2:35pm
143 Views
Post# 23729458

RE:RE:ZENITH: PATENTS, FUNDING, JOURNAL REVIEW, ETC. TOPICS INFO

RE:RE:ZENITH: PATENTS, FUNDING, JOURNAL REVIEW, ETC. TOPICS INFOGV, re. #2 while the specific ZEN-3365 disaster is a disaster a bigger problem IMO and i scoffed at before is the DM pump about how far ahead he always claims RVX/Zenith is ahead9 10 years or so is that his pump) and i scoffed for great reason and the ZEN-3365 is the "tell" cause: a) if so far ahead and poof they get out IP'ed it means they wasted many years or b) more likely DM doesn't really know what the entirety of the industry is up to and those pumps are more a show of ignorance than anything else (fyi as in presentatin Oncoethix ??? is what 2 years into their PI trial)...
Bullboard Posts